✦ LIBER ✦

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

✍ Scribed by Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta

Book ID: 118202521
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 327 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70490-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of advanced hepatocellular car

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study

✍ Jean-Claude Barbare; Olivier Bouché; Franck Bonnetain; Laetitia Dahan; Catherine 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 346 KB

A randomized placebo-controlled study of

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma

✍ Man-Fung Yuen; Ronnie Tung-Ping Poon; Ching-Lung Lai; Sheung-Tat Fan; Chung-Mau 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Thymostimulin versus placebo for palliat

Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial

✍ Matthias M Dollinger; Christine Lautenschlaeger; Joachim Lesske; Andrea Tannapfe 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 748 KB

Intravenous aflibercept for treatment of

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Walter H Gotlieb; Frederic Amant; Suresh Advani; Chanchal Goswami; Hal Hirte; Di 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 196 KB

Selumetinib plus docetaxel for KRAS-muta

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

✍ Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vanste 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 336 KB

A phase II study of sunitinib as a secon

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

✍ Jun Ho Yi; Sumitra Thongprasert; Jeeyun Lee; D.C. Doval; Se Hoon Park; Joon Oh P 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 275 KB